Two-period crossover study investigating the clinical pharmacokinetic similarity of the etanercept biosimilar CHS 0214 to Enbrel in healthy volunteers

Trial Profile

Two-period crossover study investigating the clinical pharmacokinetic similarity of the etanercept biosimilar CHS 0214 to Enbrel in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Etanercept (Primary)
  • Indications Autoimmune disorders; Plaque psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Coherus Biosciences
  • Most Recent Events

    • 12 Nov 2013 New trial record
    • 28 Oct 2013 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top